Bristol-Myers Squibb Company

The filings describe a company with a single operating segment, a broad oncology and immunology pipeline, and a Legacy Portfolio still facing generic erosion. The forensic screens give mixed signals, and none of them is a fraud alarm. The Beneish M-Score of -2.684 is below the -1.78 threshold and is not in the elevated manipulation-risk zone; this is a screening output, not a finding about the company's accounts. The Altman Z-Score of 2.16 sits in the grey zone between 1.10 and 2.60, which means the model does not place the company clearly in either distress or safety territory. The Piotroski F-Score is 7 of 8 computable signals, a checklist of profitability, leverage and efficiency tests, though it does not capture pricing exposure. The Fog Index of 20.30 is above 18, the label for very hard to read, so the MD&A requires careful effort. The balance sheet shows clearer improvement: long-term debt fell to $42.85 billion from $47.6 billion, and equity rose to $18.47 billion from $16.34 billion. Liabilities still equal about 79% of the $90.04 billion asset base. Pipeline items such as iberdomide, mezigdomide, Camzyos in adolescents, and the 13 early-stage assets from the May 2026 Hengrui agreement add optionality, but the MD&A warns that Medicare maximum fair prices for Eliquis and Pomalyst could accelerate revenue erosion. Readers may want to look at how these pricing rules affect the Growth Portfolio over the next few years.

Catalyst.According to the 10-Q MD&A, revenue rose 6% in the second quarter of 2026 to $12,973 million and 4% year to date to $24,462 million, driven by higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis, partly offset by generics in the Legacy Portfolio. Management points to pipeline items including FDA acceptance of an NDA for iberdomide with a PDUFA date of August 17, 2026, and an sNDA for Camzyos in adolescents with a PDUFA date of September 30, 2026. Gross-to-net adjustments fell to 32% of gross product sales year to date from 46% a year earlier, lifting net product sales to $23,756 million from $22,794 million. Management also expects annual cost savings of approximately $2.0 billion by the end of 2027.

Hidden risk.The 2025 annual numbers are less strong than the growth narrative suggests. Revenue was $48.19 billion in 2025 versus $48.3 billion in 2024, about 0.2% lower, and operating cash flow fell to $14.16 billion from $15.19 billion, roughly 6.8% lower. The 2026 gross-to-net drop is large, and the 10-Q notes that a $331 million reduction to prior-period provisions was recognized in the first half of 2025, which distorts year-over-year comparisons. The MD&A also states that Inflation Reduction Act maximum fair prices for Eliquis took effect January 1, 2026, and that tariff relief through January 2029 may be terminated or not extended. Readers may want to look at the pricing risk factors before relying on the recent growth trend.